Synthesis and activity of small molecule GPR40 agonists.
The first report on the identification and structure-activity relationships of a novel series of GPR40 agonists based on a 3-(4-{[N-alkyl]amino}phenyl)propanoic acid template is described. Structural modifications to the original screening hit yielded compounds with a 100-fold increase in potency at the human GPR40 receptor and pEC(50)s in the low nanomolar range. The carboxylic acid moiety is not critical for activity but typically elicits an agonistic response higher than those observed with carboxamide replacements. These compounds may prove useful in unraveling the therapeutic potential of this receptor for the treatment of Type 2 diabetes.
Garrido
Dulce M
DM
GlaxoSmithKline Research and Development, 5 Moore Drive, Research Triangle Park, NC 27709, USA.
Corbett
David F
DF
Dwornik
Kate A
KA
Goetz
Aaron S
AS
Littleton
Thomas R
TR
McKeown
Steve C
SC
Mills
Wendy Y
WY
Smalley
Terrence L
TL
Briscoe
Celia P
CP
Peat
Andrew J
AJ
D000473:Alkanes / Q000138:chemical synthesis* / Q000494:pharmacology*; D000818:Animals; D016466:CHO Cells; D006224:Cricetinae; D006801:Humans; D011422:Propionates / Q000138:chemical synthesis* / Q000494:pharmacology*; D043562:Receptors, G-Protein-Coupled / Q000819:agonists*; D013329:Structure-Activity Relationship
D000473:Alkanes; C473034:FFAR1 protein, human; D011422:Propionates; D043562:Receptors, G-Protein-Coupled